Carvedilol CAS 72956-09-03 Puritas >99.0% (HPLC)

Description:

Chemical Name: Carvedilol

CAS: 72956-09-03

Puritas: >99.0% (HPLC)

Aspectus: Crystallinus Powder Alba

Contactus: Dr

Mobile/Wechat/Whatsapp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Shanghai Ruifu Chemical Co., Ltd. est opificem Carvedilol (CAS: 72956-09-03) magna qualitate.Ruifu Chemical traditio totius terrarum, quantitatis competitive pretium, optimum servitium, parvas et moles in promptu habere potest.Purchase Carvedilol,Please contact: alvin@ruifuchem.com

Related Intermedia:

Intermedia Carvedilol

N-(2-(2-Methoxyphenoxy)ethyl)benzylamine Hydrochloride	CAS: 3246-03-5
2-(2-Methoxyphenoxy) Ethylaminum Hydrochloridum Hydrate	CAS 64464-07-9
2-(2-Methoxyphenoxy)	CAS 1836-62-0
4-(2,3-Epoxypropoxy)carbazole	CAS 51997-51-4
4-Hydroxycarbazole	CAS 52602-39-8
1,3-Cyclohexanedione	CAS 504-02-9
Carvedilol	CAS 72956-09-03
Carvedilol Phosphate Hemihydrate	CAS 610309-89-2

Chemical Properties:

Nomen chemicum	Carvedilol
Synonyma	1-(9H-Carbazol-4-yloxy) -3-[[2-(2-Methoxyphenoxy)ethyl]amino]-2-Propanol;Artist;Cadilan;Carca;Cardivas;Carloc;Carvas;Carvedilol;Carvediol;Coreg;DQ 2466;Dilatrend;Dimitone;Eucardic;Korvasan;Kredex;Querto;Talliton;BM-14190
Stock Status	In Stock, GMP Commercial
CAS Number	72956-09-3
Formulae hypotheticae	C24H26N2O4
M. Pondus	406.48 g/mol
Liquescens punctum	115.0 ad 119.0℃
Density	1.250±0.06 g/cm3
Solubilitas in aqua	Insolubilis in aqua
Solubilitas	Solutum in Methanol.Leviter solutum in Ethanol, Ether
Repono Nativ.	Frigus & siccum (2~8℃)
COA & MSDS	Praesto
Brand	Ruifu Chemical

Specifications:

Items	Signa inspectionis	Proventus
Aspectus	Crystallina pulveris alba	Obsequitur
Damnum in Siccatio	≤0.50% (105℃ pro 3 h)	0.25%
Residere in Ignition	≤0.10%	0.07%
Substantiae cognatae
Totalis immunditias	≤0.50%	Obsequitur
immunditiam A	≤0.20%	Obsequitur
immunditia C	≤0.04%	Obsequitur
Alia individua immunditia	≤0.10%	Obsequitur
Metalla gravia (Pb)	≤10ppm	<10ppm
Puritas / Analysis Methodus	>99.0% (HPLC)	99.72%
Infrared Imaginis	Conformat ut Structure	Obsequitur
conclusio	Productum probatum & obsequitur cum specificationibus

Sarcina / at /naviportans:

Sarcina:Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.
Repono Condition:Condite in arcte clauso vase.Condite in loco frigido, sicco (2~8℃) et cellario bene ventilato ab substantiis incompossibilibus.A luce et humore protege.
Naviportans:Libera ad mundum ab aere, per FedEx / DHL Express.Ieiunium et certas traditiones provide.

commoda:

Satis capacitas: sufficientes facilities et technici

Professional Service: One stop acquireing service

Altera Package: Custom sarcina ac titulus praesto

Ieiunium Delivery: Si intra stirpem, tres dies partus praestatur

Supple firmum: Esse rationabile stirpe

Technical Support: Technology solution praesto

Custom Synthesis Service: Range from P. to kilos

High Quality: Constitutus ratio completa qualitas certitudinis

FAQ:

Quam mercari?Quaeso contactumDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com

15 Years Experience?Plus quam XV annos experientiae habemus in fabricando et exportando amplis intermediis pharmaceuticis vel alchimicis pharmaceuticis amplis.

Mercatus principalis?Vendere mercatum domesticum, Americam septentrionalem, Europam, Indiam, Coream, Iaponicam, Australiam etc.

Commodi?Superior qualitas, parabilis pretium, officia professionalia et subsidia technica, ieiunium partus.

Qualitasfides?Qualitas strictioris temperantiae ratio.Pro instrumento analysi professionali includuntur NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Claritas, Solubilitas, Microbialis limes test, etc.

Exempla?Pleraque producta praebent exempla gratuita pro qualitate aestimationis, sumptus naviculas a clientibus solvendos.

Factory Audit?Factory audit gratissimum.Quaeso ante constitutum.

MOQ?Nec MOQ.Parvus ordo placet.

Tempus adferendi? Si intus prosapia, tres dies partus praestatur.

Transportatio?Per Express (FedEx, DHL), ab Air, per Mare.

Documenta?Post servitium venditionis: COA, MOA, ROS, MSDS, etc. praeberi possunt.

Consuetudo Synthesis?Consuetudo synthesis officia praebere potest ad optimas investigationes tuas necessitates aptandas.

Pensio conditio?Proforma cautionis primum post confirmationem ordinis mittetur, informationes nostrae ripae inclusas.Payment by T/T (Telex Transfer), PayPal, Western Union, etc.

72956-09-3 - Salutis Information:

Hazard Codes N,Xn
Periculum Denunciationes 51/3-336/37/38-20/21/22
Salus Denunciationes 61-36-26
RIDADR UN 3077 9/PG 3
WGK Germania 3
RTECS UA8670000
HazardClass IRRITANT
PackingGroup III
Periculosae substantiae Data 72956-09-3 (Ancipitia substantiae Data)
Toxicity LD50 oralis in cane: >1gm/kg

72956-09-3 -Applicatio:

Carvedilol (CAS: 72956-09-03) vasodilateri beta obstructore utilis est in curatione hypertensionis et angina pectoris.Praeter pressuram sanguinis deprimendam, carvedilol resistentiam vascularium totalem decrescit sine tachycardia reflexa plerumque cum vasodilatoribus occurrentibus.Ferunt bene toleratos renum effectus parcendo.

Carvedilol primum in Belgium anno 1985. Hoc productum alpha et beta receptores impedire potest, nulla actio intrinseca, in concentratione alto de modo cum calcii contradictione.Validum effectum habet interclusionis beta receptores, quae venas sanguineas dilatare possunt, resistentiam periphericam et pressionem sanguinis inferiorem minuere, et parum valere in rate cordis et cardiacis.Fusce adhiberi potest pro prima hypertensione et angina pectoris.

72956-09-3 - USP 35 Standard:

DEFINITIO

Carvedilol continet NLT 98.0% et NMT 102.0% C24H26N2O4, in fundamento siccato computatum.

IDENTIFICATIO

• A. Absorptio infrared <197K>

• B. Retentionis tempus maioris apicem solutionis Sample respondet solutioni vexilliferorum, prout habetur in Assay.

TEMPTATIO

• De modo procedendi

Buffer: 2.72 g/L potassii monobasici phosphatis.Acidum phosphoricum dilutum ad pH 2.0 compone.

Mobile phase: Acetonitrile et Buffer (31:69)

Solutio aptabilitas systematis: 0.05 mg/mL uterque USP Carvedilol RS et USP Carvedilol Compone A RS in tempore Mobili

Solutio mensurae: 0.04 mg/mL of USP Carvedilol RS in Mobili phase .

Sample solutio: 0.04 mg/mL Carvedilolae in tempore Mobili

Systema chromatographicum

(Vide Chromatographiam <621>, Ratio idoneitatis.)

Modus: LC

Detector: UV 240 nm

Columna: 4.6-mm × 15-cm;5-µm stipare L7

Columna temperatus: 55℃

Fluunt rate: 1 mL/min

Currite tempus: 60 min

Iniectio amplitudo: 10 µL

Ratio convenientia

Sample: Ratio idoneitatis solutionis

Convenientia requisita

Resolutio: NLT 4.0 inter carvedilolum et carvedilolum compositum A . relatum

Tendens factor: NMT 1.5 ad carvedilolum apicem

Relativum vexillum declinationis: NMT 2%

Analysis

Exempla: Standard solution et Sample solutionem

Recipis carvedilol (C24H26N2O4) in portione exempli sumpta;

Proventus = (rU/rS) (CS/CU) 100

rU=	apicem responsio carvedilol ex Sample solution
rS =	apicem responsio carvedilol ex Standard solutione
CS=	concentratio carvedilol in solutione Standard (mg/mL)
CU=	intentio Carvedilol in Sample solutionis (mg/mL)

Acceptatio criteria: 98.0%-102.0% in fundamento exsiccato

IMPURITIES

• Residuum in Ignitione <281>: NMT 0,1% e 1 g

• Metalla gravia, Methodus II <231>: NMT 10 ppm .

• Impuritates organicae, De modo procedendi 1 : [Nota ratione immunitatum praesentes, vel immunitates organicas, procedendi 1 vel immunitates organicas, procede 2. Impuritates organicae, modo procedendi 2 commendatur cum carvedilolo mixto F affinis est potentia immunditia.]

Quiddam et tempus mobile: Para ut in primordium.

Solutio aptabilitas systematis: 0.05 mg/mL uterque USP Carvedilol RS et USP Carvedilol Compone C RS in Mobili phase

Solutio Standard: 1 µg/mL singulae USP Carvedilol RS, USP Carvedilol Compone A RS, USP Carvedilol Compone B RS, USP Carvedilol Compone D RS, et USP Carvedilol Compone E RS, et 0.2 µg/mL USP Carvedilol Related Compone C RS in Mobile tempus

Sample solutio: 1 mg/mL Carvedilolae in tempore Mobile

Systema chromatographicum

(Vide Chromatographiam <621>, Ratio idoneitatis.)

Modus: LC

Detector: Dual wavelength, UV 220 and 240 um.Utere 220 um pro carvedilolo quantitatis composito E cognato, uti 240 um pro carvedilolo et omnibus aliis compositis affinibus.

Columna: 4.6-mm × 15-cm;5-µm stipare L7

Columna temperatus: 55℃

Fluunt rate: 1 mL/min

Iniectio amplitudo: 20 µL

Ratio convenientia

Sample: Ratio idoneitatis solutionis

Convenientia requisita

Resolutio: NLT 17 inter carvedilolum et carvedilolum compositum C . cognatum

Analysis

Exempla: Standard solution et Sample solutionem

Recipis carvedilol affinis compositi A, carvedilol affinis compositi B, carvedilol affinis compositi C, carvedilol affinis compositi D, carvedilol affinis compositi E, et quaevis alia immunditia in portione Carvedilol sumpta;

Proventus = (rU/rS) (CS/CU) 100

rU	=	apicem responsionis compositi affinis congruentis vel quaelibet alia immunditia ex Sample solutione
rS	=	apicem responsionis congruentis actis compositis ex solutione Latin.Ad calculandum recipis cuiuslibet alterius individui immunditiae utantur cacumine responsionis carvedilol.
CS	=	concentratio compositionis cognatae compositi in solutione Standard (mg/mL).Ad computandum recipis immunitates quascumque alias pro CS, concentratione USP Carvedilol RS utere.
CU	=	intentio Carvedilol in Sample solutionis (mg/mL)

Re- gulae acceptationis: Vide Tabula 1 .

Table 1

Nomen	Relativum Retentionis Tempus	Acceptatio Criteria, NMT (%)
Carvedilol cognata composita Ea	0.35	0.1
Carvedilol cognata composita Ab	0.52	0.1
Carvedilol inde bisalkylpyrocatechol (si praesens)c	0.70	0.15
Carvedilol	1.0	-
Carvedilol affinis compositi Cd	3.6	0.02
Carvedilol cognata composita De	5.0	0.1
Carvedilol affinis compositi Bf	8.5	0.1
Alia singula immunditia	-	0.10
Summa immunditiae	-	0.5g
a 2-(2-Methoxyphenoxy) ethyl amine. b 1-(4-(2-hydroxy-3-(2-(2-methoxyphenoxy)ethylamino)propoxy)-9H-carbazol-9-yl)-3-(2-(2-methoxyphenoxy)ethylamino -ol. c 3,3¢-{2,2¢-[1,2-Phenylenebis(oxy)]bis(ethane-2,1-diyl)}bis(azanediyl)bis(1-(9H-carbazol-4-yloxy) propan-2-ol). d 1-(9H-Carbazol-4-yloxy)-3-(benzyl(2-(2-methoxyphenoxy)ethyl)amino)propan-2-ol. e 4-(Oxiran-2-ylmethoxy)-9H-carbazole. f 3,3¢-(2-(2-Methoxyphenoxy)ethylazanediyl)bis(1-(9H-carbazol-4-yloxy)propan-2-ol). g Neglegere omnem immunditiam minus quam 0.01%.

• Impuritates organicae, De modo procedendi 2

Solutio A: Acidum acetonitrile et trifluoroaceticum (100:0.1).

Solutio B: Acidum trifluoroaceticum et aqua (0.1:100)

Diluente: Acidum acetonitrile, trifluoroaceticum, et aqua (22:0.1:78).

Mobile phase: See Table 2

Table 2

Tempus (min)	Solutio A (%)	Solutio B (%)
0	22	78
20	22	78
33	38	62
45	38	62
55	55	45
65	55	45
68	22	78
80	22	78

Solutio systematis idoneitatis: 1.0 mg/mL de USP Carvedilol Systema Suitability Mixtura RS in Diluent

Sample solutio: 1 mg/mL Carvedilol in Diluent

Systema chromatographicum

(Vide Chromatographiam <621>, Ratio idoneitatis.)

Modus: LC

Detector: UV 240 nm

Columna: 4.6-mm x 15-cm;5-µm stipare L68

Columna temperatus: 30℃

Fluunt rate: 1.4 mL/min

Iniectio amplitudo: 20 µL

Ratio convenientia

Sample: Ratio idoneitatis solutionis

Convenientia requisita

Resolutio: NLT 1.8 inter carvedilolum et carvedilolum compositi F . affinis

Analysis

Sample: Sample solution

Recipis cujusque immunditiae rationem in portione Carvedilol sumptae;

Proventus = (rU/rT) 100

rU	=	apicem responsio pro qualibet immunditia in Sample solutionem
rT	=	perorare omnium ad apicem respondeo in Sample solutione

Re- gulae acceptationis: Vide Tabula III.

Table 3

Nomen	Relativum Retentio Tempus	Acceptatio Criteria, NMT (%)
Carvedilol cognata composita Aa	0.7	0.1
Carvedilol	1.0	-
Carvedilol affinis compositi Fb	1.2	0.1c
N-Isopropylcarvedilold	1.6	0.1
Carvedilol affinis compositi Ce	1.8	0.02
Carvedilol affinis compositi Bf	2.1	0.1
Biscarbazoleg	3	0.1
Alia singula immunditia	-	0.1
Summa immunditiae	-	0.5
a 1-(4-(2-hydroxy-3-(2-(2-methoxyphenoxy)ethylamino)propoxy)-9Hcarbazol-9-yl)-3-(2-(2-methoxyphenoxy)ethylamino) propan-2-ol . b 1-(2-(2-Methoxyphenoxy)ethylamino)-3-(6,7,8,9-tetrahydro-5H-carbazol-4-yloxy)propan-2-ol. c Haec immunditia quantitatem adhibens procedendi sub immunditiis organicis, modo procedendi 3: Carvedilol Compone F. Related Compone. d. e 1-(9H-Carbazol-4-yloxy)-3-(benzyl(2-(2-methoxyphenoxy)ethyl)amino)propan-2-ol. f 3,3'-(2-(2-Methoxyphenoxy)ethylazanediyl)bis(1-(9H-carbazol-4-yloxy)propan-2-ol). g 1,3-Bis-(9H-carbazol-4-yloxy)-2-propanol.

• Organic Impurities, De agendi ratione III: Carvedilol Related Compone F (si praesens)

Solutio A: Acidum trifluoroaceticum et aquaticum (0.5:100)

Solutio B: Methanolum et acidum trifluoroaceticum (100:0.5)

Diluente: aqua et acetonitrile (1:1).

Mobile phase: Solutio A et Solutio B (65:35).

Solutio systematis idoneitatis: 1.5 mg/mL de USP Carvedilol Systema Suitability Mixtura RS in Diluent

Sample solutio: 1.5 mg/mL Carvedilolae in Diluent praeparato hoc modo.Utere circiter 1.9 mL de Diluent per mg Carvedilol, et sonicare breviter ad solutionem faciliorem.

Systema chromatographicum

(Vide Chromatographiam <621>, Ratio idoneitatis.)

Modus: LC

Detector: UV 226 nm

Columna: 4.6-mm × 30-mm;3-µm stipare L7

Columna temperatus: 40℃

Fluunt rate: 2 mL/min

Iniectio amplitudo: 10 µL

Ratio convenientia

Sample: Ratio idoneitatis solutionis

Convenientia requisita

Resolutio: NLT 2.0 inter carvedilolum et carvedilolum compositum F . relatum

Analysis

Sample: Sample solution

Recipis carvedilol referentis compositi F computare in portione exempli sumpta;

Exitus = (rU/rT) (1/F) 100

rU	=	apicem responsionis carvedilol affinis compositi F ex Sample solutione
rT	=	summa cacumen responsionum carvedilol et carvedilol compositae F affinis ex solutione Sample
F	=	relativum responsionis factor, 1.1

Acceptatio criteria: NMT 0.1%

IN SPECIE TESTS

• Damnum in remittit <731>: sicca specimen ad 105℃ pro 3 h: amittit NMT 0.5% sui ponderis.

ADDITICIUS REQUISITIS

• Packaging and storage : Conserve in strictis vasis , et repone ad temperatura cella moderata .

• Labeling: Si probatio immunitatum organicarum ab HPC alio quam modo procedendi 1 adhibetur, tunc testatio exprimit probationem quibus articulus obtemperat.

• USP Signa Reference <11>

USP Carvedilol RS

USP Carvedilol Related Compone RS
1-(4-(2-hydroxy-3-(2-(2-methoxyphenoxy)ethylamino)propoxy)-9H-carbazol-9-yl)-3-(2-(2-methoxyphenoxy)ethylamino) propan-2- ol.
C36H43N3O7 629.74

USP Carvedilol Related Compone B RS
3,3'-(2-(2-Methoxyphenoxy)ethylazanediyl)bis(1-(9H-carbazol-4-yloxy)propan-2-ol).
C39H39N3O6 645.74

USP Carvedilol Related Compone C RS
1-(9H-Carbazol-4-yloxy)-3-(benzyl(2-(2-methoxyphenoxy)ethyl)amino)propan-2-ol.
C31H32N2O4 496.60

USP Carvedilol Related Compone D RS
4-(Oxiran-2-ylmethoxy)-9H-carbazole.
C15H13NO2 239.27

USP Carvedilol Related Compone E RS
2-(2-Methoxyphenoxy)ethyl amine.
C9H13NO2 167.21

USP Carvedilol Ratio Suitability Mixture RS
Mixtura circiter 0.1% carvedilol affinis compositi F (1-(2-(2-methoxyphenoxyi)ethylamini)-3-(2,3,4,9-tetrahydro-1H-carbazol-5-yloxy) propan-2-ol) in vulva carvedilol medicamento substantia.